New Zealand markets closed

BIIB Mar 2023 200.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
84.260.00 (0.00%)
At close: 11:15AM EST
Full screen
Previous close84.26
Expiry date2023-03-17
Day's range80.10 - 84.26
Contract rangeN/A
Open interest28
  • Motley Fool

    Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock

    When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.

  • Zacks

    Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

    Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.

  • GlobeNewswire

    Lecanemab Receives Priority Review Status in Japan

    TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis